Resveratrol promotes osteogenesis and alleviates osteoporosis by inhibiting p53

Aging (Albany NY). 2020 May 27;12(11):10359-10369. doi: 10.18632/aging.103262. Epub 2020 May 27.

Abstract

Although osteoporosis is one of the most common chronic age-related diseases, there is currently no gold standard for treatment. Evidence suggests resveratrol, a natural polyphenolic compound, may be helpful in the treatment of osteoporosis and other diseases. However, the molecular mechanisms underlying the anti-osteoporotic effects of resveratrol remain largely unknown. In the present study, KEGG pathway enrichment analysis of resveratrol-targeted genes identified 33 associated pathways, 12 of which were also involved in osteoporosis. In particular, the MDM2/p53 signaling pathway was identified as a potential key pathway among the shared pathways. In vitro experiments indicated that MDM2-mediated p53 degradation induced osteoblast differentiation, and resveratrol could partially reverse p53-dependent inhibition of osteogenic differentiation. These findings suggest resveratrol may alleviate osteoporosis at least in part by modulating the MDM2/p53 signaling pathway.

Keywords: KEGG pathways; bioinformatics analysis; bone mass density; osteoporosis; resveratrol.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Differentiation / drug effects*
  • Cells, Cultured
  • Computational Biology
  • Datasets as Topic
  • Humans
  • Mesenchymal Stem Cells
  • Mice
  • Osteogenesis / drug effects*
  • Osteoporosis / drug therapy*
  • Osteoporosis / pathology
  • Resveratrol / pharmacology*
  • Resveratrol / therapeutic use
  • Tumor Suppressor Protein p53 / antagonists & inhibitors*
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • TP53 protein, human
  • Trp53 protein, mouse
  • Tumor Suppressor Protein p53
  • Resveratrol